Amgen secures $70m in biosimilar clash with Hospira
26-09-2017
Federal Circuit rejects Amgen biosimilar discovery request
11-08-2017
AndreyPopov / iStockphoto.com
Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Hospira, patent, patent infringement, biosimilar, Biologics Price Competition and Innovation Act, anaemia
